Evotec AG has entered into a research agreement with Biogen Idec, under which Evotec will use its protein production technologies, assay development and high throughput screening to identify hit molecules for Biogen. Evotec will screen a target selected by Biogen with the option to add further targets. Additionally, Biogen will have access to Evotec’s full range of screening technologies and library of compounds, and will use its expertise in protein production and assay development to develop new assays for the target.

Dr. Mark Ashton, Evotec’s executive vice president, business development, said, “We believe that the quality of future drug candidates is very much dependent on the identification of high quality starting points. To this end we have established a platform of screening technologies that have been proven to identify high-class hit molecules. We are looking forward to working with Biogen Idec and identifying interesting hit compounds for them.”

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference